
Please try another search
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company focused on advancing cancer therapies based on novel deoxyribonucleic acid (DNA) damage response (DDR) technologies. The Company’s research programs include kt-2000, kt-3000 and kt-4000 The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating deoxyribonucleic acid (DNA) double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review